Literature DB >> 15309413

p38 and JNK have distinct regulatory functions on the development of apoptosis during simulated ischaemia and reperfusion in neonatal cardiomyocytes.

A-M Engelbrecht1, C Niesler, C Page, A Lochner.   

Abstract

Rat neonatal ventricular myocytes exposed to simulated ischaemia and reperfusion (SI/R) were used as an in vitro model to delineate the role(s) of extracellular signal-regulated kinase (ERK), p38 and c-Jun NH(2)-terminal protein kinase (JNK), as well as PKB in apoptosis. Exposure of the myocytes to SI (simulated ischaemia - energy depletion induced by KCN and 2-deoxy- D-glucose) reduced cell viability, as measured by the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay, and stimulated apoptosis as evidenced by caspase-3 activation and poly(ADP-ribose) polymerase (PARP) cleavage. However, morphological evidence of increased apoptosis, detected by staining with Hoechst 33342, was only seen in response to reperfusion. This suggests that although ischaemic conditions are sufficient to induce cellular markers of apoptosis (PARP cleavage and caspase-3 activation), reperfusion is required to complete the apoptotic pathway in these cells. Furthermore, SI resulted in a rapid, strong, biphasic activation of p38 concomitant with a weak and transient activation of the two ERK isoenzymes, p42/p44-MAPK. Reperfusion for 5 minutes resulted in a strong phosphorylation of p42/p44-MAPK, while no additional p38 activation was seen at this stage. On the other hand, p46/p54-MAPK (JNK) was phosphorylated in response to 5 minutes of reperfusion only and not during SI alone. A peak of PKB/Akt (Ser(473)) activity was seen within 5 minutes of exposure to SI, whereas PKB/Akt (Thr(308)) phosphorylation remained at the baseline level. Both PKB/Akt phosphorylation sites (Ser(473) and Thr(308)) were phosphorylated after 5 minutes of reperfusion. Inhibition of PI-3-kinase activity, using wortmannin, decreased phosphorylation on both sites during SI. However, only SI/R-induced PKB/Akt phosphorylation on Thr(308) was reduced by wortmannin. Myocytes pre-treated with SB203580, a p38-inhibitor, displayed a significant increase in cell viability [63.67 +/- 1.85 to 84.33 +/- 4.8% (p < 0.05)] and attenuation of the apoptotic index during SI/R [22.6 +/- 2.94% to 9 +/- 0.43% (p < 0.001)], while SP600125, a specific JNK inhibitor, caused a significant increase in caspase-3 activation [1.66 +/- 0.03 fold to 2.56 +/- 0.27 fold (p < 0.001)] and apoptotic index [22.6 +/- 2.94% to 32.75 +/- 6.13% (p < 0.05)]. However, PD98059, an ERK inhibitor, failed to affect apoptosis during SI/R. Inhibition of PI-3-kinase prevented the increase in mitochondrial viability usually observed during reperfusion. Interestingly, wortmannin caused a significant increase in PARP cleavage during reperfusion, but had no effect on caspase-3 activation or the apoptotic index. Our results suggest that p38 has a pro-apoptotic role while JNK phosphorylation is protective in our cell model and that these kinases act via caspase-3 to prevent or promote cell survival in response to SI/R-induced injury.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15309413     DOI: 10.1007/s00395-004-0478-3

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  26 in total

1.  gp-91 mediates histone deacetylase inhibition-induced cardioprotection.

Authors:  Ting C Zhao; Ling X Zhang; Guangmao Cheng; Jun T Liu
Journal:  Biochim Biophys Acta       Date:  2010-04-28

Review 2.  Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale.

Authors:  Beth A Rose; Thomas Force; Yibin Wang
Journal:  Physiol Rev       Date:  2010-10       Impact factor: 37.312

3.  SIRT1 modulates MAPK pathways in ischemic-reperfused cardiomyocytes.

Authors:  Matteo Becatti; Niccolò Taddei; Cristina Cecchi; Niccolò Nassi; Paolo Antonio Nassi; Claudia Fiorillo
Journal:  Cell Mol Life Sci       Date:  2012-02-05       Impact factor: 9.261

4.  Transient and sustained oxidative stress differentially activate the JNK1/2 pathway and apoptotic phenotype in H9c2 cells.

Authors:  Anastasia Pechtelidou; Isidoros Beis; Catherine Gaitanaki
Journal:  Mol Cell Biochem       Date:  2007-12-04       Impact factor: 3.396

Review 5.  Myocardial AKT: the omnipresent nexus.

Authors:  Mark A Sussman; Mirko Völkers; Kimberlee Fischer; Brandi Bailey; Christopher T Cottage; Shabana Din; Natalie Gude; Daniele Avitabile; Roberto Alvarez; Balaji Sundararaman; Pearl Quijada; Matt Mason; Mathias H Konstandin; Amy Malhowski; Zhaokang Cheng; Mohsin Khan; Michael McGregor
Journal:  Physiol Rev       Date:  2011-07       Impact factor: 37.312

6.  Targeted deletion of NF-kappaB p50 diminishes the cardioprotection of histone deacetylase inhibition.

Authors:  L X Zhang; Y Zhao; G Cheng; T L Guo; Y E Chin; P Y Liu; T C Zhao
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-04-09       Impact factor: 4.733

7.  Caveolin and β1-integrin coordinate angiotensinogen expression in cardiac myocytes.

Authors:  Hind Lal; Suresh K Verma; Hao Feng; Honey B Golden; Fnu Gerilechaogetu; Damir Nizamutdinov; Donald M Foster; Shannon S Glaser; David E Dostal
Journal:  Int J Cardiol       Date:  2012-10-09       Impact factor: 4.164

Review 8.  Crosstalk between mitogen-activated protein kinases and mitochondria in cardiac diseases: therapeutic perspectives.

Authors:  Sabzali Javadov; Sehwan Jang; Bryan Agostini
Journal:  Pharmacol Ther       Date:  2014-06-09       Impact factor: 12.310

9.  Chlorogenic acid analogues from Gynura nepalensis protect H9c2 cardiomyoblasts against H2O2-induced apoptosis.

Authors:  Bang-Wei Yu; Jin-Long Li; Bin-Bin Guo; Hui-Min Fan; Wei-Min Zhao; He-Yao Wang
Journal:  Acta Pharmacol Sin       Date:  2016-09-05       Impact factor: 6.150

10.  Cardiomyopathy in offspring of diabetic rats is associated with activation of the MAPK and apoptotic pathways.

Authors:  Benjamin E Reinking; Elesa W Wedemeyer; Robert M Weiss; Jeffrey L Segar; Thomas D Scholz
Journal:  Cardiovasc Diabetol       Date:  2009-07-31       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.